Innovent
Innovent
Innovent including oncology
Innovent is a leading biotechnology company in China. It aims to produce highly complex and affordable biopharmaceutical products for patients. Since its inception, Innovent has established a product chain of 13 new drugs covering four major disease areas, including oncology, ophthalmology, autoimmune diseases and cardiovascular diseases, and has undertaken 7 National Science and Technology Projects, of which 5 products were selected for the National "Major New Drug Creation" Program and 1 product was selected for the National Key Research and Development Program. Special "Precision Medicine Research".
- All
- News
- Analysis
- Research
Briefing May 24, 2022 09:50 AM
· Healthcare
Shuoxing biological innovative nano multi antibody sm3321 was approved by ind in the United States
Briefing May 24, 2022 09:45 AM
· Healthcare
Temasek's reduction of Cinda biological
In-depth
Healthcare
EqualOcean Sector Quarterly Report - Healthcare Sectors
To help worldwide investors keep track of what is happening in each industry or sector and the related hot spots, we launched the EqualOcean Sector Quarterly Report series, which gathers notable information and statistics in each quarter.
Apr 07, 2022 01:44 PM
Briefing May 20, 2022 10:53 AM
· Healthcare
Haizheng pharmaceutical and Junshi biology signed a contract for commissioned production of Xinguan oral drug vv116
Briefing May 17, 2022 10:54 AM
· Healthcare
Heavy bomb in the field of hypoglycemic! Lilly tirzepatide approved for listing
Apr 22, 2021 03:11 PM
Research
Healthcare, Consumer Staples, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Healthcare, Technology, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing May 11, 2022 03:53 PM
· Healthcare
Roche PD-L1 combined with tigit failed in the first-line treatment of stage III non-small cell lung cancer with high expression of PD-L1
Briefing May 11, 2022 02:46 PM
· Healthcare
Foreign media said Green Valley pharmaceutical Alzheimer's disease new drug phase IX phase I ® The international phase III clinical trial has been stopped
Briefing May 11, 2022 02:18 PM
· Healthcare
The new drug registration of step pharmaceutical subsidiary was terminated, and 7.6 million R & D expenses have been invested
Briefing May 10, 2022 09:32 PM
· Healthcare
Pfizer acquired biohaven for about US $11.6 billion to expand the product pipeline of nervous system diseases
Briefing Apr 27, 2022 06:47 PM
· Healthcare
Medtronic's world's first self expanding pulmonary valve was first-class recalled
Briefing Apr 26, 2022 03:52 PM
· Healthcare
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
Healthcare
Biopharmaceutical Firm Sinogen Raises Tens of Millions of US in Pre-Series B Round
Founded in 2016, Sinogen has established a technology platform to study the mechanisms of an oncolytic virus targeting tumor cells and completed the preclinical study of SGN1, genetic engineering product that can accurately and rapidly dissolve tumors.
May 24, 2022 07:45 PM
Healthcare, Financials
Junshi Announces Its Anti-Covid Phase III Drug Reaches Primary Endpoint
Founded in August 2021, Juntuo Biotech is dedicated to the R&D processes in biomedicine and vaccines. The company's innovative R&D pipelines cover viral vaccines, bacterial vaccines, genetically engineered vaccines, conjugate vaccines, and multivalent vaccines.
May 24, 2022 03:45 PM
Briefing Apr 26, 2022 03:43 PM
· Healthcare
The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.
Briefing Mar 01, 2022 08:18 AM
· Healthcare
Cinda biology and Baoyuan medicine announced that taretinib was included in the breakthrough therapeutic drug variety
Briefing Sep 02, 2021 02:26 PM
· Healthcare
Xinda biology and JinFang medicine have reached global strategic cooperation on KRAS G12C inhibitor gfh925
See more
Related Companies
EqualOcean Analysis
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.